Rapid-Onset, Prolonged Bone Marrow Failure Following Rituximab Therapy of Follicular Lymphoma

Publisher： Karger

E-ISSN： 2296-5262|34|6|322-324

ISSN： 2296-5270

Source： Oncology Research and Treatment, Vol.34, Iss.6, 2011-05, pp. : 322-324

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Prolonged Remission in a Patient with Relapsed Follicular Lymphoma after a Single Course of Rituximab

By  

Oncology Research and Treatment, Vol. 29, Iss. 3, 2006-03 ,pp. : 90-92

Karger

Access to resources Recommend Favorite

Retreatment with rituximab offers a similar survival benefit as maintenance therapy in patients with low tumor burden follicular lymphoma

By  

CA: A CANCER JOURNAL FOR CLINICIANS, Vol. 65, Iss. 1, 2015-01 ,pp. : 1-2

John Wiley & Sons Inc

Access to resources Recommend Favorite

Immunochemotherapy with Rituximab, Vincristine and 5-Day Cyclophosphamide for Heavily Pretreated Follicular Lymphoma

By  

Oncology, Vol. 68, Iss. 2-3, 2005-07 ,pp. : 146-153

Karger

Access to resources Recommend Favorite

Low‐dose chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab in follicular lymphoma

By  

EUROPEAN JOURNAL OF HAEMATOLOGY, Vol. 94, Iss. 3, 2015-03 ,pp. : 277-278

John Wiley & Sons Inc

Access to resources Recommend Favorite

Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab

By  

CANCER, Vol. 119, Iss. 20, 2013-10 ,pp. : 3662-3671

John Wiley & Sons Inc

Access to resources Recommend Favorite